We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Novel anti-VEGF chimeric molecules delivered by AAV vectors for inhibition of retinal neovascularization.
- Authors
Pechan, P.; Rubin, H.; Lukason, M.; Ardinger, J.; DuFresne, E.; Hauswirth, W. W.; Wadsworth, S. C.; Scaria, A.
- Abstract
Vascular endothelial growth factor (VEGF) is important in pathological neovascularization, which is a key component of diseases such as the wet form of age-related macular degeneration, proliferative diabetic retinopathy and cancer. One of the most potent naturally occurring VEGF binders is VEGF receptor Flt-1. We have generated two novel chimeric VEGF-binding molecules, sFLT01 and sFLT02, which consist of the second immunoglobulin (IgG)-like domain of Flt-1 fused either to a human IgG1 Fc or solely to the CH3 domain of IgG1 Fc through a polyglycine linker 9Gly. In vitro analysis showed that these novel molecules are high-affinity VEGF binders. We have demonstrated that adeno-associated virus serotype 2 (AAV2)-mediated intravitreal gene delivery of sFLT01 efficiently inhibits angiogenesis in the mouse oxygen-induced retinopathy model. There were no histological observations of toxicity upon persistent ocular expression of sFLT01 for up to 12 months following intravitreal AAV2-based delivery in the rodent eye. Our data suggest that AAV2-mediated intravitreal gene delivery of our novel molecules may be a safe and effective treatment for retinal neovascularization.Gene Therapy (2009) 16, 10–16; doi:10.1038/gt.2008.115; published online 17 July 2008
- Subjects
VASCULAR endothelial growth factors; NEOVASCULARIZATION inhibitors; RETROLENTAL fibroplasia; IMMUNOGLOBULIN genes; GENE therapy; SCIENTIFIC method
- Publication
Gene Therapy, 2009, Vol 16, Issue 1, p10
- ISSN
0969-7128
- Publication type
Article
- DOI
10.1038/gt.2008.115